Related references
Note: Only part of the references are listed.Global Tuberculosis Report 2020-Reflections on the Global TB burden, treatment and prevention efforts
Jeremiah Chakaya et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China
Wei Jing et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy
Jesper Sundell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Limited sampling strategy for predicting isoniazid exposure in patients with extrapulmonary tuberculosis
Mohammed Alshaikheid et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
Blessed Winston Aruldhas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis
Carlos A. Rodriguez et al.
THERAPEUTIC DRUG MONITORING (2019)
Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis
Piergiorgio Cojutti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis
Marlanka A. Zuur et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers
Kok-Yong Seng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
Paolo Denti et al.
PLOS ONE (2015)
Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations
L-H. Hao et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2014)
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
Simbarashe P. Zvada et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants
Jennifer J. Kiser et al.
THERAPEUTIC DRUG MONITORING (2012)
An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future
Jotam Pasipanodya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Tuberculosis: Current Situation, Challenges and Overview of its Control Programs in India
Gursimrat K. Sandhu
JOURNAL OF GLOBAL INFECTIOUS DISEASES (2011)
New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability
Tawanda Gumbo
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Estimating N-acetyltransferase metabolic activity and pharmacokinetic parameters of isoniazid from genotypes in Chinese subjects
Bing Chen et al.
CLINICA CHIMICA ACTA (2009)
Multidrug-resistant and extensively drug-resistant tuberculosis: The new face of an old disease
Laurie Anne Ferguson et al.
JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS (2009)
GENETIC POLYMORPHISM IN N-ACETYLTRANSFERASE (NAT): POPULATION DISTRIBUTION OF NAT1 AND NAT2 ACTIVITY
Katy Walker et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS (2009)
Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid
P. R. Donald et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population
B Chen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
H McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?
M Kinzig-Schippers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Isoniazid pharmacokinetics-pharmaco dynamics in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine
M Weiner et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy
D Honeybourne et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
N-acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients
T Kita et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2001)
Share Paper
